APA (7th ed.) Citation

Burns, B., Evans, E., Kudchadkar, R., Mallow, C., Reilly, C., Zauderer, M., . . . Parker, D. (2023, November). 629 Neoadjuvant SEMA4D inhibitor pepinemab combination with nivolumab increases crosstalk between B cell and CD26hi T cell in patients with resectable stage III melanoma. Journal for ImmunoTherapy of Cancer.

Chicago Style (17th ed.) Citation

Burns, Brian, et al. "629 Neoadjuvant SEMA4D Inhibitor Pepinemab Combination with Nivolumab Increases Crosstalk Between B Cell and CD26hi T Cell in Patients with Resectable Stage III Melanoma." Journal for ImmunoTherapy of Cancer Nov. 2023.

MLA (9th ed.) Citation

Burns, Brian, et al. "629 Neoadjuvant SEMA4D Inhibitor Pepinemab Combination with Nivolumab Increases Crosstalk Between B Cell and CD26hi T Cell in Patients with Resectable Stage III Melanoma." Journal for ImmunoTherapy of Cancer, Nov. 2023.